Grifols (GRFS) Assets (2009 - 2025)
Grifols' (GRFS) quarterly Assets came in at $22.9 billion in Q4 2025, little changed YoY from $22.9 billion in Q4 2024, and little changed on a QoQ basis from $22.9 billion in Q4 2024.
Grifols (GRFS) Assets (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Assets data on file, last reported at $22.9 billion in Q4 2025.
- Quarterly Assets changed 0.32% year-over-year to $22.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.9 billion (changed 0.32% YoY) and the FY2025 annual result came in at $22.9 billion, up 28227.93% from the prior year.
- Assets was little changed at $22.9 billion in Q4 2025, from $22.9 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $22.9 billion in Q4 2025 to a low of $21.7 billion in Q4 2022.
- A 5-year average of $22.4 billion and a median of $22.6 billion in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2021 — Assets increased 20.82% — and 2022, when it slipped 1.56%.
- Tracing GRFS's Assets over 5 years: stood at $22.0 billion in 2021, then fell by 1.56% to $21.7 billion in 2022, then increased by 4.28% to $22.6 billion in 2023, then advanced by 1.27% to $22.9 billion in 2024, then advanced by 0.32% to $22.9 billion in 2025.
- The last three Assets figures came in at $22.9 billion (Q4 2025), $22.9 billion (Q4 2024), and $22.6 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 470.18 Bn | 463.61 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.85 Bn | 369.71 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.42 Bn | 252.52 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 182.16 Bn | 178.98 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.30 Bn | 147.60 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 106.12 Bn | 101.95 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Grifols | 5.43 Bn | 4.43 Bn | - | 22.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.95 Bn |
| Dec 31, 2024 | 22.87 Bn |
| Dec 31, 2023 | 22.59 Bn |
| Dec 31, 2022 | 21.66 Bn |
| Dec 31, 2021 | 22.00 Bn |
| Dec 31, 2020 | 18.21 Bn |
| Sep 30, 2020 | 18.28 Bn |
| Mar 31, 2020 | 17.55 Bn |
| Dec 31, 2019 | 17.20 Bn |
| Sep 30, 2019 | 15.62 Bn |
| Mar 31, 2019 | 15.22 Bn |
| Dec 31, 2018 | 14.24 Bn |
| Sep 30, 2018 | 13.70 Bn |
| Jun 30, 2018 | 13.65 Bn |
| Mar 31, 2018 | 16.45 Bn |
| Dec 31, 2017 | 12.86 Bn |
| Jun 30, 2017 | 12.22 Bn |
| Dec 31, 2016 | 10.94 Bn |
| Sep 30, 2016 | 10.68 Bn |
| Jun 30, 2016 | 10.78 Bn |